POZEN INC.
®
THE JOURNEY CONTINUES »
Jefferies 2Jefferies 2ndnd Annual Annual Healthcare ConferenceHealthcare Conference
June 26, 2008June 26, 2008
2
POZENINC.
® Forward-Looking Statements
The following presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval or our failure to achieve milestones that would have provided us with revenue; the receipt of future development, regulatory or sales milestones and royalty payments from our collaboration partners, the failure to obtain approval of our product candidates, including for reasons arising from, among other reasons, differences in the FDA's interpretation of the results of studies or trials from that of POZEN's and FDA's judgment that the benefits of the drug do not outweigh its risks; our inability to know with certainty what standards the FDA will use to evaluate drug candidates and how that may change or evolve over time, our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; our dependence on our collaboration partners for the sales and marketing of our products once approved, including our dependence on GlaxoSmithKline for the sales and marketing of Treximet, competitive factors; our inability to protect our patents or proprietary rights of others; general economic conditions; our failure to successfully commercialize our product candidates; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and on our Form 10-Q for the period ended March 31, 2008. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
3
POZENINC.
®
POZEN is a Small Pharmawith Strong Fundamentals
• Efficient business model
• Experienced management team
• Model self funding since 2000 IPO
• Strong cash position
• Profitable two of last three years
• “Best in class” next generation migraine product launched by market leader
• Innovative pipeline with significant commercial potential
4
POZENINC.
® Strong Financial Position
Million
Million
>$50.0
29.7
Expected Net Cash at Year EndNo DebtShares Outstanding
Million$33736
Market Capitalization at 6/25/08Employees
MillionMillion
$62.6$20.0
Cash at 3/31/08Treximet Milestones in Q2 08
Financial Overview
5
POZENINC.
® Efficient, Low Cash Burn Business Model
0
10
20
30
40
50
60
70
80
2004 2005 2006 2007 2008 Est.
Fixed Expenses R&D Project Costs Cash Revenue
Revenue / R&D Project Costs / Fixed Expenses* / Cash
* Fixed expenses exclude non-cash stock-based compensation costs in all years
Cash
Revenue
$ (m
illio
ns)
6
POZENINC.
®
Key Components of POZEN’s Successful Business Model
• Experienced management team
• In-house creativity generates products with real value to patients and doctors
• Issued patents for all products
• Efficient development programs
• Rapid advancement from Proof of Concept to Phase 3
• Joint development teams through NDA approval
• Partners responsible for manufacturing/commercialization• No fixed infrastructure costs to POZEN
• No sales and marketing expenses
• Sales royalties/milestones generate income beginning immediately with launch
7
POZENINC.
®
Innovative Solutions for Unmet Patient Needs
Formulation Phase I Phase II Phase III NDA Market
TreximetTM (GSK)Migraine
PA32540Aspirin Product
PA08140Use with NSAIDs
PA32520/50040Possible Pain/ Cancer Doses
Product
PN 400 (AZN)Arthritis Product
8
POZENINC.
® TreximetTM – “The Future Is Here”
9
POZENINC.
® POZEN’s Income Potential from Treximet
• Upfront and milestone payments received $80 Million• Potential sales milestones $80 Million
Royalty on Net Sales
$74 million2010 analysts’ consensus revenue estimate
High teens on all salesBeginning January 2010
Mid-single digits until sales threshold, then high teens
Until December 2009
10
POZENINC.
®
2010 Analyst Consensus Estimates for Treximet
0102030405060708090
100
2010
Revenue and Expense Estimates for Treximet
Revenue $74m
$ (m
illio
ns)
Expected Expense
$0
11
POZENINC.
® ROI of Treximet Through Q1 2008
$82.1
$25.7
$0.0$10.0$20.0$30.0$40.0$50.0$60.0$70.0$80.0$90.0
$100.0
Revenue Direct Development Costs
Mill
ions
Treximet ROI > 3X
* Does not include cost of R&D personnel or any allocation of overhead expenses
12
POZENINC.
®
Why Should Treximet Be Successful for GSK and POZEN?
• Treximet is different than the rest• Superior efficacy to market leader• Next generation product with multiple mechanisms of action• AEs similar to individual components• Patient friendly dose pack• Competitive pricing
• 80% of migraine patients are willing to try a new product (Bigal, et al)• Three issued POZEN patents listed in Orange Book
• First expiry 2017, last expiry 2025
• GSK has the resources (and intends to use them)• Commitment from senior management• Proven migraine sales and marketing teams• Able to fund a major product launch• Committed to the needs of the migraine patient
For full prescribing information see www.treximet.com
13
POZENINC.
®
Sustained pain free 2-24 hours
Pain free at 2 hours
Sustained absence of phonophobia
Sustained absence of photophobia
Sustained absence of nausea
Reduction in vomiting
Reduction in rescue medication
Treximet –Superiority Over Market Leader
Improvement vs.Sumatriptan1
60%
33%
30%
28%
18%
50%
36%1JAMA, April 4, 2007—Vol. 297, No. 13
14
POZENINC.
® Initial Performance Treximet vs. Relpax
Source: IMS NPA
4,410
9,246
14,786
6,619
0
18,793
12302000400060008000
100001200014000160001800020000
Month 1 Month 2 Month 3 Month 4 Month 5 Month 6
TRx'
s
Relpax Treximet
Relpax and TreximetMonthly Total Prescriptions from Launch
Treximet
15
POZENINC.
® Oral Triptan New Prescription Share
Source: IMS NPA
Imitrex + Amerge
Maxalt
Zomig
Relpax
Imitrex + Amerge
Maxalt
Zomig
Relpax
Axert
Frova
Treximet1.7%
April 2008April 2008 May 2008May 2008
16
POZENINC.
®
Continued Growth of A Next Generation Product After Generic Entry---Wellbutrin XL
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
1,400,000
1,600,000
Jan-03
Mar-03
May-03
Jul-0
3Sep
-03Nov
-03Ja
n-04Mar-
04May
-04Ju
l-04
Sep-04
Nov-04
Jan-05
Mar-05
May-05
Jul-0
5Sep
-05Nov
-05Ja
n-06Mar-
06May
-06Ju
l-06
Sep-06
Nov-06
Tota
l Pre
scri
ptio
ns
Wellbutrin XL Wellbutrin SRBupropion HCL SR
Wellbutrin SR and XL and SR Generic TRx
17
POZENINC.
® GSK’s Commitment to Treximet
• 2,500 GSK sales representatives attended mid-May launch meeting
• Success with managed care• 85% of covered lives unrestricted 3rd tier access
• Comprehensive promotional materials awaiting FDA approval
• Continued commitment to additional Treximet studies • > 70 abstracts and publications on Treximet
• AAN, April 2008 – 5 abstracts presented
• AHS, June 2008 – 5 abstracts to be presented
18
POZENINC.
®
Strong Commitment from GSK Senior Management
“On the launch - - we are very excited about it…it’s an opportunity to redefine the marketplace.”
“The [Treximet] opportunity is bigger than Imitrex, and it is an important product for us –we’re going to be firing with all guns blazing.”
Source: April 24, 2008 GSK Earnings Conference Call Chris Viehbacher, President, North American Pharmaceuticals
19
POZENINC.
® Why Did POZEN Choose Naproxen?
• “Naproxen does not increase the risk of heart attacks and ought to be a painkiller of choice.”
Dr. Curt Furberg serves on FDA Drug Safety and Risk Management Advisory Committee
• “For patients with arthritis or other conditions who require chronic pain relief, naproxen appears to be the safest NSAID choice from a cardiovascular perspective.”
David Graham, Cox-2 Inhibitors, Other NSAIDs and Cardiovascular Risk,Editorial, JAMA published online September 12, 2006
20
POZENINC.
®
Naproxen – Cardiovascular Risk Profile Versus Other NSAIDs
Brand/Generic Drug Name RR* 95% C.I.
Naproxen 0.97 0.87-1.07Piroxicam 1.06 0.70-1.59Celebrex (celecoxib) 1.06 0.91-1.23Ibuprofen 1.07 0.97-1.18Other NSAIDs 1.10 1.00-1.21Mobic (meloxicam) 1.25 1.00-1.55Indomethacin 1.30 1.07-1.60Low-Dose Vioxx (rofecoxib) 1.33 1.00-1.79All Vioxx (rofecoxib) 1.35 1.15-1.59Diclofenac 1.40 1.16-1.70 High-Dose Vioxx (rofecoxib) 2.19 1.64-2.91
Source: McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA published online September 12, 2006.
*Relative cardiovascular risk where 1 = neutral
21
POZENINC.
® Key Naproxen Information
• Naproxen is one of the most widely prescribed NSAIDs
• Some experts concerned about COX-2 CV toxicity recommend naproxen as the NSAID with the least CV risk potential
• Despite all these advantages, like all NSAIDs, daily naproxen use may cause ulcers in up to 40% of patients within 6 months
• Low dose aspirin use increases the risk of ulcers further
22
POZENINC.
®
Innovative Solutions for Unmet Patient Needs
Formulation Phase I Phase II Phase III NDA Market
TreximetTM (GSK)Migraine
PA32540Aspirin Product
PA08140Use with NSAIDs
PA32520/50040Possible Pain/ Cancer Doses
Product
PN 400 (AZN)Arthritis Product
23
POZENINC.
® The Time for PN is Now!
• Huge unmet medical need with serious consequences
• Arthritis is the nation’s leading cause of disability
• 46 million people suffer from arthritis in the U.S.1
• 750,000 hospitalizations, 36 million outpatient visits
• By 2030, nearly 67 million adults will suffer from arthritis1
• NSAIDs are leading treatment for arthritis but usage complicatedby GI toxicity risk
• Stomach complications in patients taking NSAIDs appear to be on the rise due to gap between NSAID prescriptions and therapies providing GI protection2
1 Centers for Disease Control and Prevention (CDC), January 20082 American College of Rheumatology Annual Meeting 2008
24
POZENINC.
®
PN 400 – Designed to Meet the Needs and Concerns of Patients and Doctors
• Not a COX-2 NSAID
• Naproxen efficacy and safety profile – OA, RA, AS
• Potentially reduce risk of developing a gastric ulcer, with or without concomitant aspirin use
• Anticipate better GI tolerability than naproxen
• Intended to greatly simplify regimen for patients relying on gastroprotective therapy + NSAID
• Novel dosage form ensures sequential delivery with every dose
• “Drugs don’t work in patients who don’t take them!”
25
POZENINC.
®
26
POZENINC.
® PN – Sequential Delivery Profile
(μg/
mL)
PN 100–103 Plasma Time – Concentration Curves for Naproxen and PPI on Day 1Proof of Concept study
0
50
100
150
200
250
300
350
0 2 4 6 8 10 12Time (hrs)
PPI
0
5
10
15
20
25
30
35
40
45
50
Nap
roxe
n
PPI Naproxen 500 mg
27
POZENINC.
® Anti-Arthritis Oral Market – US
84%
15%
Source: IMS National Sales Perspective, IMS National Prescription Audit™, 2004 & 2007
Total Prescriptions2004 2007
1%
54%
45%
1%
Cox-2sGI ProtectPlain NSAIDs
$6.5 Billion $2.6 Billion
28
POZENINC.
® AstraZeneca Deal Structure
• Total upfront and milestone payments received $70 Million
Milestones and Royalties
POZEN will receive low double digit royalties based on net U.S. sales and tiered royalties ex-U.S.
$260 millionSales performance milestones based on achievement of certain sales thresholds
$55 millionDevelopment and regulatory milestones
29
POZENINC.
® PN 200-301 – Study Features
• Similar design to PN 400 pivotal Phase 3 trials
• Primary endpoint
• Incidence of gastric ulcers (>3 mm diameter with depth) over 6 months
• Secondary endpoints
• Incidence of DU over 6 months
• Tolerability
• Safety
30
POZENINC.
®
PN 200-301 Primary Endpoint –Incidence of Gastric Ulcers - ITT
0
10
20
30
40
1 month 3 months 6 months
Gas
tric
ulc
ers,
cum
ulat
ive
%72% RR
*
3.4%
10.3%
5.1%
23.1%
8.3%
29.4%
* p<0.001 between groups over 6 months
PN200 (n=206)
EC naproxen (n=203)
31
POZENINC.
®
0
10
20
30
40
PN 200-301 – Cumulative Incidence of Gastric Ulcers at 6 Months – ASA vs no ASA
No ASA ASA
NaproxenNaproxenn=151
PN200PN200n=150
NaproxenNaproxenn=52
PN200PN200n=56
69% RRp<0.001
69% RRp=0.012
NSNS
Gas
tric
ulc
ers,
%
6.7%
21.9%
8.9%
28.8%
32
POZENINC.
® PN 200-301 Study Results
• Demonstrated significant reduction in gastric ulcers compared to EC naproxen
• PN 200 significantly reduced gastric ulcers of concomitant aspirin users
• Increases potential of success for PN 400 Phase 3 study
• Earned $20 million milestone payment
33
POZENINC.
® PN 400 – Efficient Development Plan
• Arthritis patients at risk (two pivotal studies)• PN 400 vs. EC naproxen alone (twice daily)• Primary endpoint: cumulative incidence of gastric ulcers at
6 months
• Appropriate clinical pharmacology studies
• 12-month open label safety study
• NDA targeted 1H 2009
• Additional studies to determine how product could potentially benefit patients
34
POZENINC.
®
Innovative Solutions for Unmet Patient Needs
Formulation Phase I Phase II Phase III NDA Market
TreximetTM (GSK)Migraine
PA32540Aspirin Product
PA08140Use with NSAIDs
PA32520/50040Possible Pain/ Cancer Doses
Product
PN 400 (AZN)Arthritis Product
35
POZENINC.
®
PA – Designed to Meet the Needs and Concerns of Patients and Doctors
• Only NSAID without a black box
• Aspirin efficacy and safety profile
• Potentially reduce risk of developing a gastric ulcer, with or without concomitant NSAID use
• Anticipate better GI tolerability than aspirin
• Intended to greatly simplify regimen for patients relying on gastroprotective therapy + aspirin
• Novel dosage form ensures sequential delivery with every dose
• “Drugs don’t work in patients who don’t take them!”
36
POZENINC.
®
Aspirin Reduces Risks of Cardiovascular Events
• Compelling evidence from studies involving over 140,000 patients• 22% reduction in new serious cardiovascular (CV) events• 30% reduction in both vascular deaths and myocardial infarction
• Risks of serious vascular events reduced in patients:• 46% with unstable angina• 33% with stable angina• 23% with peripheral arterial disease• 53% undergoing coronary angioplasty
• Aspirin substantially reduces risk of death and further CV events in high CV risk
Source: Aspirin Foundation Website – Article on Secondary Prevention
37
POZENINC.
® Gastrointestinal Toxicity of Aspirin
• Gastric ulcers are common toxicity of aspirin, even ≤325 mg/day
• Risk increases significantly with age, especially >60
• Fatality rate for patients admitted to hospital for GI hemorrhage due to gastric ulcers is approximately 5-10%
• Low dose aspirin believed to be responsible for up to 1/3 of all mortality attributed to NSAID-related GI complications
Source: Alimentary Pharmacy & Therapeutics; Underutilization of Gastroprotective Strategies in Aspirin Users at Increased Risk of Upper GI Complication; Targownik, L.E.; Metge, C.J.; Leung, S.; 2008
38
POZENINC.
® 3 PA Proof of Concept Studies Completed
• Three proof of concept studies completed
• PA32520 vs. 325 mg EC aspirin• 28 day treatment, 40 patients per arm• Endoscopy – baseline, 14, 28 days
• PA32520 vs. 81 mg EC aspirin• 28 day treatment, 40 patients per arm• Endoscopy – baseline, 14, 28 days
• PA32540 vs. 325 mg EC aspirin• 28 day treatment, 40 patients per arm• Endoscopy – baseline, 14, 28 days
39
POZENINC.
® PA – Pooled Endoscopic Data
0
10
20
30
40
50
GU/ D U Lanza Sco res 3 & 4
Pooled Endoscopic Data
2.52.475.13
13.75
2.5
9.9
20.5
42.5
PA32540 (n=40)
PA32520 (n=81)
EC ASA 81 (n=39)
EC ASA 325 (n=80)
40
POZENINC.
®
Progress on the PA32540 Development Program
Develop a stable, patient friendly dosage form suitable for mass production
Demonstrate bioequivalence of PA32540 dosage form to EC aspirin
Complete all pre-clinical work, if any
Complete Proof of Concept Phase 1 studies
Submit SPA
Prepare clinical trial materials for Phase 3 program
41
POZENINC.
® Important Events for POZEN
• 2008 – Treximet performance
• 3Q 08 – Results of bioequivalence studies for PN 400
• 3Q 08 – Results of SPA for PA32540
• 2H 08 – Completion of PN 400 pivotal studies
• 2H 08 – Completion of PN 400 vs Celebrex studies
• 2H 08 – PA32540 Phase 3 studies ready for initiation
• 1H 09 – Data analysis and filing of PN 400 NDA
POZEN INC.
®
THE JOURNEY CONTINUES »
WWW.POZEN.COMWWW.POZEN.COM